Skip to content

Reference Values for Gastric Emptying Scintigraphy After Bariatric Surgery

Reference Values for Gastric Emptying Scintigraphy After Bariatric Surgery

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06391255
Acronym
SCATTER
Enrollment
50
Registered
2024-04-30
Start date
2024-05-29
Completion date
2025-05-31
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery, Gastric Emptying

Brief summary

Oesophageal and gastric scintigraphy evaluates the function of the gastrointestinal system including variables such as oesophageal transit and gastric emptying (GE). Some variables are known to change after bariatric surgery. In patients that have symptoms of pain or nausea after bariatric surgery, oesophageal and gastric scintigraphy plays an important role in determining the nature of symptoms and is necessary for adequate treatment. However, literature on reference values in the bariatric population are scarce. At this moment, quantitative evaluation of the scintigraphy cannot be performed and conclusions are based on visual interpretation. There is a need for a standardised scintigraphy protocol for the population that underwent bariatric surgery taking into account the changed anatomy and physiology. Then, reference values that describe the oesophageal transit and GE assessed using scintigraphy have to be determined.

Interventions

oesophageal and gastric emptying

Sponsors

Rijnstate Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 18 and 65 years; * RYGB or SG as primary bariatric surgery; * A 2 year post-operative period without significant peri-operative or postoperative complications that could affect oesophageal transit, GE, or weight loss; * Normal weight loss, according to our expectations (25% \< TWL \< 35%); * Participants must be able to adhere to the study visit schedule and protocol requirements; * Participants must be able to give informed consent (IC) prior to any study procedures; * Willing to be informed about incidental findings of pathology and approving of reporting this to their general physician.

Exclusion criteria

* Pre-existent oesophageal or gastric motility disorders, dysphagia, reflux, dumping syndrome, (postprandial) abdominal pain, neurological or metabolic conditions that significantly affect oesophageal or gastric motility; * When using proton pump inhibitors (PPI) or H2-antagonists, the inability to stop using them for 3 days; * Using opioids; * Previous oesophago-gastric surgery, other than bariatric surgery; * Unable to stop smoking for 24h; * Pregnancy or breast-feeding; * Patients with a drug or alcohol addiction; * Gluten intolerance; * Intolerance to tracer ingredients; * Participating in another scientific study at the same time, if this study interferes with the current study in any way.

Design outcomes

Primary

MeasureTime frameDescription
reference values for RYGB and GS patients2-3 yearsgastric emptying (T1/2 \[min\], retention \[%/min\], caloric emptying \[cal/min\], GE curve over time)
to describe SPECT/CT images and determine its benefit for anatomical correlation in asymptomatic (reference) and symptomatic population.2-3 years
to define reference values for RYGB- and SG-patients for oesophageal scintigraphy after bariatric surgery using an optimised protocol;2-3 yearstransit time \[min\], emptying rate \[%/min\]

Secondary

MeasureTime frame
to explore the correlation of GE and oesophageal transit, and weight loss results or symptoms, using prospective data from this study and retrospective data from symptomatic patients and similar studies previously2-3 years

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026